156 results about "Somatic antigen" patented technology

The invention provides an mVSV virus vector, i.e., attenuated mVSV obtained after multiple modification mutations occur to an M protein amino acid site of a wild Indiana strain VSV, and an optimized heterologous antigen gene is preferentially integrated to a double cloning site area of an mVSV packaging core plasmid pmVSV-Core at the same time. The mVSV virus vector vaccine comprises a heterologous antigen gene which fuses or embeds a target virus between G and L genes of an mVSV vector envelope, wherein the antigen gene comprises an enveloped and embedded antigen gene encoding the target virus, an embedded combination antigen gene or a fused antigen gene; the mVSV virus vector is embedded or fused with a dominant antigen of spike protein S of an SARS-CoV-2 pathogen; the dominant antigen is preferably selected from a receptor binding domain of spike protein S, namely RBD; and a COVID-19 vaccine based on mVSV mediation is formed. The vaccine has good prevention or treatment effect on COVID-19 infected people.

The present invention provides a virus like particle comprising a virus structural protein and an antigen derived from PD-1 or a ligand of PD-1, and a composition or kit comprising thereof, its use in immune response etc.

The present invention relates to a transplant rejection in an animal suppressed by administration of an antibody directed at a cell surface antigen selected from the group consisting of CD4, CD8, CD154, LFA-1, CD80, CD86 and ICAM-1, preferably an anti-CD4 antibody, together with a non-cellular protein antigen to generate in the animal a population of regulatory T-lymphocytes; reactivating said population of regulatory T-lymphocytes by further administration to the animal of the non-cellular protein antigen; and transplanting said organ or tissue whilst said population of regulatory T-lymphocytes is activated. Regulatory T cells can be generated ex vivo by culturing T cells with an antibody directed at a cell surface antigen selected from the group consisting of CD4, CD8, CD154, LFA-1, CD80, CD86 and ICAM-1, in the presence of cells that present either alloantigen or a non-cellular protein antigen. Ex vivo generated T-lymphocytes can be used as an alternative method of overcoming transplant rejection or in combination with the in vivo method. A similar approach can be adopted for the treatment of autoimmune conditions.

The invention relates to novel molecule detection signal amplification technique, which is characterized in that the molecule detection signal amplification technique is a biomolecule detection method with high sensitivity which is formed by streptavidin, an antigen, an antibody, polypeptide and the like which are marked by quantum dots through tyramine signal amplification and silver strengthening dyeing signal amplification. The detection method comprises the following steps: the biomolecule to be detected is combined with nucleic acid, the antibody, the antigen, the polypeptide and the like which are fixed on a solid phase material, the quantum dots are introduced to molecule to be detected through biomolecule specificity combination, silver strengthening dyeing is carried out on the quantum dots by using silver dyeing reagents, and signals are amplified. Obtained signals can be scanned through common optical scanners, analyzed through common imaging instruments or observed through naked eyes. The detection method achieves high sensitivity detection of the biomolecule on one hand, and reduces application cost of biomolecule detection on the other hand.

The invention relates to an antigen binding site for binding to a P2X₇ receptor, the antigen binding site being de-fined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

The invention provides monoclonal antibodies against the duck Tembusu virus, an antigen detection kit and application. According to the invention, the DTMUV-JXSP cell strain of the duck Tembusu virus is used as immunogen for preparation of the monoclonal antibodies which include monoclonal antibodies respectively secreted by hybridoma cells with respective accession numbers of CGMCC No. 8104, CGMCC No. 8107 and CGMCC No. 8106; the monoclonal antibody 3B4 secreted by the hybridoma cell with the accession number of CGMCC No. 8106 is used as a primary antibody coated ELISA plate, the monoclonal antibody 3F2 secreted by the hybridoma cell with the accession number of CGMCC No. 8107 is subjected to enzyme labeling and used as an ELISA secondary antibody, so the double-antibody sandwiched detection kit is established and the kit has good sensitivity and specificity. According to the invention, effective means are provided for large-scale clinical detection of the duck Tembusu virus.

The invention relates to an ELISA (enzyme-linked immunosorbent assay) kit for an EV (enterovirus) 71 inactivated vaccine antigen. The detection kit comprises an EV71 pre-coated polyclonal antibody ELISA plate, a sample diluent, a second antibody, an enzyme-labeled antibody, a concentrated cleaning solution, an enzyme substrate solution and a stop buffer, wherein the ELISA plate is pre-coated with a polyclonal antibody prepared by taking recombinant EV71 structural protein 1 as an immune source; the second antibody adopts a monoclonal antibody prepared by taking keyhole limpet hemocyanin coupled polypeptide sequence FGEHKQEKDL as the immune source; the enzyme-labeled antibody adopts a horse radish peroxidase labelled goat anti-mouse immunoglobulin antibody; and an antibody standard is placed in the kit. The ELISA kit has better sensitivity when measuring the titer of the EV71 inactivated vaccine antigen, and has better linearity in the range of 5.9-750 ng/ml, and the linearly dependent coefficient r2 is larger than 0.99. The kit for measuring the titer of the EV71 inactivated vaccine antigen simply and conveniently has good specificity, accurate quantification, high sensitivity and good repeatability.

The invention discloses an indirect ELISA detection method for detecting a porcine epidemic diarrhea virus antibody and a kit thereof. The recombinant porcine epidemic diarrhea virus COE protein is successfully expressed by cloning a gene for encoding the COE protein into a eukaryotic expression vector pPIC9K and then transforming the eukaryotic expression vector pPIC9K into a pichia pastoris GS115 competent cell for inducible expression. Compared with a prokaryotic expression inclusion body antigen, the purification production process of the COE protein is simple, convenient and feasible, andthe COE protein is high in expression quantity and purity and is closer to a virus protein natural structure; the COE protein is used as a coating antigen; the indirect ELISA detection method for detecting the porcine epidemic diarrhea virus antibody and the kit thereof are successfully constructed, the detection results of the method and the kit thereof are high in accuracy, strong in specificity, high in sensitivity and good in repeatability, and the kit needs a small amount of samples, is simple, convenient and rapid to operate and is low in cost; therefore, the method and the kit thereofhave a wide application prospect in detection of the porcine epidemic diarrhea virus antibody.

The invention provides a vaccine composition. The vaccine composition comprises an immune amount of an avian newcastle disease virus antigen, an avian infectious bronchitis virus antigen and an avian mycoplasma synoviae antigen and a carrier. The invention further provides a preparation method and application of the vaccine composition. The immune effect of the trigeminal vaccine is superior to the immune effect of combining newcastle disease-infectious bronchitis inactivated vaccines with mycoplasma synoviae inactivated single vaccine. The invention further provides a vaccine composition which contains a mycoplasma gallisepticum antigen in addition to the three antigens, and can be used for effectively resisting attack of four pathogens.

The invention discloses an application method of a tumor cell-derived exosome antigen in a DC vaccine. The invention discloses a preparation method of a tumor vaccine, which comprises the following step: sensitizing DC cells by using a tumor cell exosome to obtain the tumor vaccine. The tumor cell supernatant exosome provided by the invention has good stability, low toxicity and good cell compatibility, and is convenient to operate and apply and popularize in clinical tumor immunotherapy, and the method is a simple, feasible and practical application technology and method. The problems that inexisting DC vaccine construction, antigen sources are lacked, compatibility is poor, instability is caused, and an external DC antigen carrier has biotoxicity and is difficult to operate are solved.

An antigen-specific T-cell response to alloantigen, tissue-specific antigen (e.g., islet antigen or other autoantigens involved in autoimmune disease), or self (or host) antigen is detected at an early stage of graft rejection or recurrent autoimmunity. An increase in cytotoxic lymphocyte gene (CLG) expression in peripheral blood is a risk factor for development of deleterious immune responses, which may be confirmed by functional assays. For example, the distinction between production of regulatory or inflammatory cytokines by T cells may dissect the type of immune response which is being induced: the survival of transplanted islet cells used to treat type 1 diabetes may be monitored, loss of the transplant by graft rejection (i.e., an alloantigen target) may be distinguished from autoimmune disease (i.e., a self or host antigen target).

The invention discloses a kit of Mycobacterium tuberculosis and a detection method thereof. The kit contains an enzyme-linked immunosorbent assay (ELISA) plate, a biotin-labeled single-stranded DNA adaptor, horseradish peroxidase-labeled streptavidin and a chromogenic substrate. In the detection method provided by the invention, the biotin-labeled single-stranded DNA adaptor of Mycobacterium tuberculosis H37Rv is used as a probe and a method which is similar to the indirect enzyme-linked immunosorbent assay (ELISA) method is adopted to detect Mycobacterium tuberculosis; and Mycobacterium tuberculosis or sputum to be detected or a body fluid sample, and a control sample are added in the ELISA plate for incubation, Mycobacterium tuberculosis combined with the plate is trapped by the biotin-labeled single-stranded DNA adaptor and then washed, the horseradish peroxidase-labeled streptavidin is added, the substrate is added for developing, and the optical density (OD) value is detected by a microplate reader after developing when the absorption wavelengh is 450nm. When the kit provided by the invention detects Mycobacterium tuberculosis or the Mycobacterium tuberculosis or somatic antigen in sputum, blood and body fluid, the detection speed is high, the detection is convenient and safe, the detection time can be saved, the efficiency is high, the cost is low, the detection sensitivity and accuracy are high, and the application prospect is wide.

The invention relates to a double antibody sandwich enzyme-linked immuno sorbent assay (ELISA) method for detecting a peanut allergic component Arah1, which belongs to the technical field of immunoassay. The method comprises the steps of firstly acquiring peanut protein with higher purity containing Arah1 from fresh peanut kernels, utilizing the peanut protein to immunize a mouse to acquire 14 strains of monoclonal antibodies, and selecting a combination of the monoclonal antibodies with maximal P/N value as an optimum combination. The antibody and an enzyme-labeled antibody, which are connected onto a solid-phase carrier, are respectively combined with two antigenic determinants on an antigen molecule to be detected in a sample to form a solid antibody-antigen-enzyme-labeled antibody immune compound. Since the quantity of the solid-phase antibody and the enzyme-labeled antibody is excessive relative to the antigen to be detected in the reaction system, the formation quantity of the compound is in proportion to the content of the antigen to be detected. The content of the antigen to be detected can be determined by determining the color matter amount (OD value) generated when the enzyme in the compound acts on the added substrate. The double antibody sandwich ELISA method is direct and quick, has high sensitivity, high specificity, high accuracy and high precision, is simple to operate and is used for detecting the peanut allergic component Arah1.

The invention relates to the technical field of ELISA detection kits, and particularly discloses a high-capacity asphalt/epoxy resin-based hard carbon negative electrode material and a preparation method of same. The kit includes a box body, in which two ELISA plates coated with anti-CD63 cloning antibody, an ELISA plate coated with anti-CA125 cloning antibody, 10 ml of HPR-labeled CA125 antibody,10 ml of HPR-labeled CD63 antibody, 20 ml of H2O2 being a color developing agent A solution, 20 ml of TMB being a color developing agent B solution, and two bottles of 5 ml of stop solution. Comparedwith the prior art, by means of the exosome ELISA method, an antigen of the ovarian cancer is quickly detected, thus completing early diagnosis on the ovarian cancer. The kit is high in detection accuracy and specificity and is extensive in detectable sample range, which may include serum, ascites, blood plasma, tissue liquid and the like. The kit is short in reaction period and has good effect.

The invention relates to a chicken Eimeria acervulina immunoregulation type DNA vaccine, which belongs to the technical field of biological veterinary medicines. The molecular biology technology is used for connecting lactate dehydrogenase genes of schizont antigen of the first generation of chicken Eimeria acervulina and chIL-2 genes in series to construct a fusion expressing vaccine pVAX-LDH-IL-2. The vaccine comprises a plurality of T cell immune response elements, thus preventing and curing chicken coccidiosis effectively.

The invention discloses a human growth differentiation factor-15 magnetic particle chemiluminescence detection kit and application thereof, the kit contains a liquid reagent R1 of a GDF15 monoclonal antibody 1 marked with FITC, a liquid reagent R2 of a GDF15 monoclonal antibody 2 marked with ALP, a magnetic particle reagent R3 coupled with an anti-FITC antibody, a calibration product and a quality control product, the GDF15 monoclonal antibody 1 and the GDF15 monoclonal antibody 2 are monoclonal antibodies with different antigen recognition epitopes, and the GDF15 monoclonal antibody 1 and the GDF15 monoclonal antibody 2 and a growth differentiation factor-15 can form a compound in an antibody-antigen-antibody form. The GDF15 is detected through a magnetic particle chemiluminescence method, the method is high in detection speed, high in sensitivity, large in detection flux and easy to operate in clinical detection, full-automatic operation can be achieved on a luminescence instrument, time and labor are saved, and convenience and rapidness are achieved.